

Chronic Inflammatory Processes May Prevent Malignancies

Helvaci MR^{1*}, Cayir S², Halici H², Sevinc A¹, Camci C¹, Abyad A³ and Pocock L⁴

¹Specialist of Internal Medicine, MD, Turkey

²Manager of Writing and Statistics, Turkey

³Middle-East Academy for Medicine of Aging, MD, Lebanon

⁴Medi-WORLD International, Australia

*Corresponding author:

Mehmet Rami Helvaci,
Specialist of Internal
Medicine, 07400, ALANYA, Turkey

Received: 06 Apr 2024

Accepted: 23 May 2024

Published: 28 May 2024

J Short Name: ACMCR

Copyright:

©2024 Helvaci MR. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and build upon your work non-commercially

Keywords:

Sickle cell diseases; Chronic inflammations; Hardened red blood cells; Capillary endothelial inflammation; Tissue hypoxia; Atherosclerosis; Malignancies

Citation:

Helvaci MR, Chronic Inflammatory Processes May Prevent Malignancies. Ann Clin Med Case Rep. 2024; V13(17): 1-12

1. Abstract

1.1. Background: The hardened red blood cells-induced capillary endothelial damage is initiated at birth, and terminate with accelerated atherosclerosis, multiorgan failures, and sudden death even at childhood in sickle cell diseases (SCD).

1.2. Methods: All cases with the SCD were included.

1.3. Results: We studied 222 males and 212 females with similar mean ages (30.8 vs 30.3 years, $p>0.05$, respectively). Disseminated teeth losses (5.4% vs 1.4%, $p<0.001$), ileus (7.2% vs 1.4%, $p<0.001$), cirrhosis (8.1% vs 1.8%, $p<0.001$), leg ulcers (19.8% vs 7.0%, $p<0.001$), digital clubbing (14.8% vs 6.6%, $p<0.001$), coronary heart disease (18.0% vs 13.2%, $p<0.05$), chronic renal disease (9.9% vs 6.1%, $p<0.05$), chronic obstructive pulmonary disease (25.2% vs 7.0%, $p<0.001$), and stroke-like atherosclerotic endpoints (12.1% vs 7.5%, $p<0.05$) were all higher but not acute chest syndrome (2.7% vs 3.7%, $p>0.05$) or pulmonary hypertension (12.6% vs 11.7%, $p>0.05$) or deep venous thrombosis and/or varices and/or telangiectasias (9.0% vs 6.6%, $p>0.05$) in males. Although the higher prevalences of acute and chronic inflammatory processes and atherosclerotic consequences even in relatively younger mean ages in both genders, there was no case of malignancy neither in males nor in females in SCD.

1.4. Conclusion: Infections, medical or surgical emergencies, or emotional stress-induced increased basal metabolic rate aggravates the sickling and capillary endothelial inflammation and ede-

ma, and terminates with disseminated tissue hypoxia, accelerated atherosclerosis, multiorgan failures, and sudden deaths even at relatively younger mean ages but not malignancies in the SCD. In another definition, chronic and systemic inflammatory processes may increase the clearance of malignant cells from the circulation.

2. Introduction

Chronic endothelial damage may be the major cause of aging and death by causing end-organ failures in human being (1). Much higher blood pressures (BPs) of the afferent vasculature may be the major accelerating factor by causing recurrent injuries on vascular endothelial cells. Probably, whole afferent vasculature including capillaries are mainly involved in the process. Thus the term of venosclerosis is not as famous as atherosclerosis in the literature. Due to the chronic endothelial damage, inflammation, edema, and fibrosis, vascular walls thicken, their lumens narrow, and they lose their elastic natures, those eventually reduce blood supply to the terminal organs, and increase systolic and decrease diastolic BPs further. Some of the well-known accelerating factors of the inflammatory process are physical inactivity, sedentary lifestyle, animal-rich diet, smoking, alcohol, overweight, chronic inflammations, prolonged infections, and cancers for the development of terminal consequences including obesity, hypertension (HT), diabetes mellitus (DM), cirrhosis, chronic obstructive pulmonary disease (COPD), coronary heart disease (CHD), chronic renal disease (CRD), stroke, peripheral artery disease (PAD), mesenteric ischemia, osteoporosis, dementia, early aging, and premature

death (2, 3). Although early withdrawal of the accelerating factors can delay terminal consequences, after development of obesity, HT, DM, cirrhosis, COPD, CRD, CHD, stroke, PAD, mesenteric ischemia, osteoporosis, and dementia-like end-organ insufficiencies and aging, the endothelial changes can not be reversed due to their fibrotic natures, completely. The accelerating factors and terminal consequences of the vascular process are researched under the titles of metabolic syndrome, aging syndrome, and accelerated endothelial damage syndrome in the literature (4-6). On the other hand, sickle cell diseases (SCD) are chronic inflammatory and highly destructive processes on vascular endothelium, initiated at birth and terminated with an advanced atherosclerosis induced end-organ insufficiencies in much earlier ages of life (7, 8). Hemoglobin S causes loss of elastic and biconcave disc shaped structures of red blood cells (RBC). Probably loss of elasticity instead of shape is the major problem because sickling is rare in peripheral blood samples of the cases with associated thalassemia minors (TM), and human survival is not affected in hereditary spherocytosis or elliptocytosis. Loss of elasticity is present during whole lifespan, but exaggerated with inflammations, infections, and additional stresses of the body. The hardened RBC induced chronic endothelial damage, inflammation, edema, and fibrosis terminate with tissue hypoxia all over the body (9). As a difference from other causes of chronic endothelial damage, SCD keep vascular endothelium particularly at the capillary level (10, 11), since the capillary system is the main distributor of the hardened RBC into the tissues. The hardened RBC induced chronic endothelial damage builds up an advanced atherosclerosis in much earlier ages of life. Vascular narrowings and occlusions induced tissue ischemia and end-organ insufficiencies are the final consequences, so the mean life expectancy is decreased by 25 to 30 years for both genders in the SCD (8).

3. Material and Methods

The study was performed in Medical Faculty of the Mustafa Kemal University between March 2007 and June 2016. All patients with the SCD were included. The SCD were diagnosed with the hemoglobin electrophoresis performed via high performance liquid chromatography (HPLC). Medical histories including smoking, alcohol, acute painful crises per year, transfused units of RBC in their lives, leg ulcers, stroke, surgical operations, deep venous thrombosis (DVT), epilepsy, and priapism were learnt. Patients with a history of one pack-year were accepted as smokers, and one drink-year were accepted as drinkers. A complete physical examination was performed by the Same Internist, and patients with disseminated teeth losses (<20 teeth present) were detected. Patients with an acute painful crisis or any other inflammatory event were treated at first, and the laboratory tests and clinical measurements were performed on the silent phase. Check up procedures including serum iron, iron binding capacity, ferritin, creatinine, liver function tests, markers of hepatitis viruses A, B, and C, a

posterior-anterior chest x-ray film, an electrocardiogram, a Doppler echocardiogram both to evaluate cardiac walls and valves, and to measure systolic BPs of pulmonary artery, an abdominal ultrasonography, a venous Doppler ultrasonography of the lower limbs, a computed tomography (CT) of brain, and a magnetic resonance imaging (MRI) of hips were performed. Other bones for avascular necrosis were scanned according to the patients' complaints. So avascular necrosis of bones was diagnosed by means of MRI (12). Associated TM were detected with serum iron, iron binding capacity, ferritin, and hemoglobin electrophoresis performed via HPLC, since the SCD with associated TM show a milder clinic than the sickle cell anemia (SCA) (Hb SS) alone (13). Systolic BPs of the pulmonary artery of 40 mmHg or higher are accepted as pulmonary hypertension (PHT) (14). The criterion for diagnosis of COPD is a post-bronchodilator forced expiratory volume in one second/forced vital capacity of lower than 70% (15). Acute chest syndrome (ACS) is diagnosed clinically with the presence of new infiltrates on chest x-ray film, fever, cough, sputum production, dyspnea, or hypoxia (16). An x-ray film of abdomen in upright position was taken just in patients with abdominal distention or discomfort, vomiting, obstipation, or lack of bowel movement, and ileus was diagnosed with gaseous distention of isolated segments of bowel, vomiting, obstipation, cramps, and with the absence of peristaltic activity. CRD is diagnosed with a persistent serum creatinine level of 1.3 mg/dL or higher in males and 1.2 mg/dL or higher in females. Cirrhosis is diagnosed with physical examination findings, laboratory parameters, and ultrasonographic evaluation. Digital clubbing is diagnosed with the ratio of distal phalangeal diameter to interphalangeal diameter of higher than 1.0, and with the presence of Schamroth's sign (17, 18). An exercise electrocardiogram is performed in cases with an abnormal electrocardiogram and/or angina pectoris. Coronary angiography is taken for the exercise electrocardiogram positive cases. So CHD was diagnosed either angiographically or with the Doppler echocardiographic findings as movement disorders in the cardiac walls. Rheumatic heart disease is diagnosed with the echocardiographic findings, too. Stroke is diagnosed by the CT of brain. Sickle cell retinopathy is diagnosed with ophthalmologic examination in patients with visual complaints. Mann-Whitney U test, Independent-Samples t test, and comparison of proportions were used as the methods of statistical analyses.

4. Results

The study included 222 males and 212 females with similar ages (30.8 vs 30.3 years, $p>0.05$, respectively). Prevalences of associated TM were similar in both genders, too (72.5% vs 67.9%, $p>0.05$, respectively). Smoking (23.8% vs 6.1%) and alcohol (4.9% vs 0.4%) were higher in males ($p<0.001$ for both) (Table 1). Transfused units of RBC in their lives (48.1 vs 28.5, $p=0.000$), disseminated teeth losses (5.4% vs 1.4%, $p<0.001$), ileus (7.2% vs 1.4%, $p<0.001$), cirrhosis (8.1% vs 1.8%, $p<0.001$), leg ulcers (19.8%

vs 7.0%, $p<0.001$), digital clubbing (14.8% vs 6.6%, $p<0.001$), CHD (18.0% vs 13.2%, $p<0.05$), CRD (9.9% vs 6.1%, $p<0.05$), COPD (25.2% vs 7.0%, $p<0.001$), and stroke (12.1% vs 7.5%, $p<0.05$) were all higher but not ACS (2.7% vs 3.7%, $p>0.05$) or PHT (12.6% vs 11.7%, $p>0.05$) or DVT and/or varices and/or telangiectasias (9.0% vs 6.6%, $p>0.05$) in males, significantly. Although the mean age of mortality (30.2 vs 33.3 years) was lower in males, the difference was not significant, probably due to the small sample size of the study cases. Although the higher prevalences of

acute and chronic inflammatory processes and atherosclerotic consequences even in relatively younger mean ages in both genders, there was no case of malignancy neither in males nor in females in the SCD (Table 2). On the other hand, mean ages of the stroke (33.5 years), COPD (33.6 years), digital clubbing (35.4 years), CHD (35.7 years), cirrhosis (37.0 years), and CRD (39.4 years) were the highest among the other atherosclerotic consequences in the SCD (Table 3).

Table 1: Characteristic features of the study cases

Variables	Male patients with SCD*	p-value	Female patients with SCD
Prevalence	51.1% (222)	Ns†	48.8% (212)
Mean age (year)	30.8 ± 10.0 (5-58)	Ns	30.3 ± 9.9 (8-59)
Associated TM‡	72.5% (161)	Ns	67.9% (144)
<i>Smoking</i>	<i>23.8% (53)</i>	<i><0.001</i>	<i>6.1% (13)</i>
<i>Alcoholism</i>	<i>4.9% (11)</i>	<i><0.001</i>	<i>0.4% (1)</i>

*Sickle cell diseases †Nonsignificant ($p>0.05$) ‡Thalassemia minors

Table 2: Associated pathologies of the study cases

Variables	Male patients with SCD*	p-value	Female patients with SCD
Painful crises per year	5.0 ± 7.1 (0-36)	Ns†	4.9 ± 8.6 (0-52)
<i>Transfused units of RBC‡</i>	<i>48.1 ± 61.8 (0-434)</i>	<i>0</i>	<i>28.5 ± 35.8 (0-206)</i>
<i>Disseminated teeth losses (<20 teeth present)</i>	<i>5.4% (12)</i>	<i><0.001</i>	<i>1.4% (3)</i>
<i>COPD§</i>	<i>25.2% (56)</i>	<i><0.001</i>	<i>7.0% (15)</i>
<i>Ileus</i>	<i>7.2% (16)</i>	<i><0.001</i>	<i>1.4% (3)</i>
<i>Cirrhosis</i>	<i>8.1% (18)</i>	<i><0.001</i>	<i>1.8% (4)</i>
<i>Leg ulcers</i>	<i>19.8% (44)</i>	<i><0.001</i>	<i>7.0% (15)</i>
<i>Digital clubbing</i>	<i>14.8% (33)</i>	<i><0.001</i>	<i>6.6% (14)</i>
<i>CHD¶</i>	<i>18.0% (40)</i>	<i><0.05</i>	<i>13.2% (28)</i>
<i>CRD**</i>	<i>9.9% (22)</i>	<i><0.05</i>	<i>6.1% (13)</i>
<i>Stroke</i>	<i>12.1% (27)</i>	<i><0.05</i>	<i>7.5% (16)</i>
PHT***	12.6% (28)	Ns	11.7% (25)
Autosplenectomy	50.4% (112)	Ns	53.3% (113)
DVT**** and/or varices and/or telangiectasias	9.0% (20)	Ns	6.6% (14)
Rheumatic heart disease	6.7% (15)	Ns	5.6% (12)
Avascular necrosis of bones	24.3% (54)	Ns	25.4% (54)
Sickle cell retinopathy	0.9% (2)	Ns	0.9% (2)
Epilepsy	2.7% (6)	Ns	2.3% (5)
ACS*****	2.7% (6)	Ns	3.7% (8)
Mortality	7.6% (17)	Ns	6.6% (14)
Mean age of mortality (year)	30.2 ± 8.4 (19-50)	Ns	33.3 ± 9.2 (19-47)

*Sickle cell diseases †Nonsignificant ($p>0.05$) ‡Red blood cells §Chronic obstructive pulmonary disease ¶Coronary heart disease **Chronic renal disease ***Pulmonary hypertension ****Deep venous thrombosis *****Acute chest syndrome

Table 3: Mean ages of the consequences of the sickle cell diseases

Variables	Mean age (year)
Ileus	29.8 ± 9.8 (18-53)
Hepatomegaly	30.2 ± 9.5 (5-59)
ACS*	30.3 ± 10.0 (5-59)
Sickle cell retinopathy	31.5 ± 10.8 (21-46)
Rheumatic heart disease	31.9 ± 8.4 (20-49)
Autosplenectomy	32.5 ± 9.5 (15-59)
Disseminated teeth losses (<20 teeth present)	32.6 ± 12.7 (11-58)
Avascular necrosis of bones	32.8 ± 9.8 (13-58)
Epilepsy	33.2 ± 11.6 (18-54)
Priapism	33.4 ± 7.9 (18-51)
Left lobe hypertrophy of the liver	33.4 ± 10.7 (19-56)
Stroke	33.5 ± 11.9 (9-58)
COPD†	33.6 ± 9.2 (13-58)
PHT‡	34.0 ± 10.0 (18-56)
Leg ulcers	35.3 ± 8.8 (17-58)
Digital clubbing	35.4 ± 10.7 (18-56)
CHD§	35.7 ± 10.8 (17-59)
DVT¶ and/or varices and/or telangiectasias	37.0 ± 8.4 (17-50)
Cirrhosis	37.0 ± 11.5 (19-56)
CRD**	39.4 ± 9.7 (19-59)

*Acute chest syndrome †Chronic obstructive pulmonary disease ‡Pulmonary hypertension §Coronary heart disease ¶Deep venous thrombosis **Chronic renal disease

5. Discussion

Acute painful crises are the most disabling symptoms of the SCD. Although some authors reported that pain itself may not be life threatening directly, infections, medical or surgical emergencies, or emotional stress are the most common precipitating factors of the crises (19). The increased basal metabolic rate during such stresses aggravates the sickling, capillary endothelial damage, inflammation, edema, tissue hypoxia, and multiorgan insufficiencies. So the risk of mortality is much higher during the crises. Actually, each crisis may complicate with the following crises by leaving significant sequelae on the capillary endothelial system all over the body. After a period of time, the sequelae may terminate with sudden end-organ failures and death during a final acute painful crisis that may even be silent, clinically. Similarly, after a 20-year experience on such patients, the deaths seem sudden and unexpected events in the SCD. Unfortunately, most of the deaths develop just after the hospital admission, and majority of them are patients without hydroxyurea therapy (20, 21). Rapid RBC supports are usually life-saving for such patients, although preparation of RBC units for transfusion usually takes time. Beside that RBC supports in emergencies become much more difficult in terminal cases due

to the repeated transfusions-induced blood group mismatch. Actually, transfusion of each unit of RBC complicates the following transfusions by means of the blood subgroup mismatch. Due to the significant efficacy of hydroxyurea therapy, RBC transfusions should be kept just for acute events and emergencies in the SCD (20, 21). According to our experiences, simple and repeated transfusions are superior to RBC exchange in the SCD (22, 23). First of all, preparation of one or two units of RBC suspensions in each time rather than preparation of six units or higher provides time to clinicians to prepare more units by preventing sudden death of such high-risk patients. Secondly, transfusions of one or two units of RBC suspensions in each time decrease the severity of pain, and relax anxiety of the patients and their relatives since RBC transfusions probably have the strongest analgesic effects during the crises. Actually, the decreased severity of pain by transfusions also indicates the decreased severity of inflammation all over the body. Thirdly, transfusions of lesser units of RBC suspensions in each time by means of the simple transfusions will decrease transfusion-related complications including infections, iron overload, and blood group mismatch in the future. Fourthly, transfusion of RBC suspensions in the secondary health centers may prevent some deaths developed during the transport to the tertiary centers for the exchange. Finally, cost of the simple and repeated transfusions on insurance system is much lower than the exchange that needs trained staff and additional devices. On the other hand, pain is the result of complex and poorly understood interactions between RBC, white blood cells (WBCs), platelets (PLTs), and endothelial cells, yet. Whether leukocytosis contributes to the pathogenesis by releasing cytotoxic enzymes is unknown. The adverse actions of WBCs on endothelium are of particular interest with regard to the cerebrovascular diseases in the SCD. For example, leukocytosis even in the absence of any infection was an independent predictor of the severity of the SCD (24), and it was associated with the risk of stroke in a cohort of Jamaican patients (25). Disseminated tissue hypoxia, releasing of inflammatory mediators, bone infarctions, and activation of afferent nerves may take role in the pathophysiology of the intolerable pain. Because of the severity of pain, narcotic analgesics are usually required to control them (26), but according to our practice, simple and repeated RBC transfusions may be highly effective both to relieve pain and to prevent sudden death that may develop secondary to multiorgan failures on the chronic inflammatory background of the SCD.

Hydroxyurea may be the only life-saving drug for the treatment of the SCD. It interferes with the cell division by blocking the formation of deoxyribonucleotides by means of inhibition of ribonucleotide reductase. The deoxyribonucleotides are the building blocks of DNA. Hydroxyurea mainly affects hyperproliferating cells. Although the action way of hydroxyurea is thought to be the increase in gamma-globin synthesis for fetal hemoglobin (Hb F), its main action may be the suppression of leukocytosis and thrombocytosis

by blocking the DNA synthesis in the SCD (27, 28). By this way, the chronic inflammatory and destructive process of the SCD is suppressed with some extent. Due to the same action way, hydroxyurea is also used in moderate and severe psoriasis to suppress hyperproliferating skin cells. As in the viral hepatitis cases, although presence of a continuous damage of sickle cells on the capillary endothelium, the severity of destructive process is probably exaggerated by the patients' own WBCs and PLTs. So suppression of proliferation of them may limit the endothelial damage-induced edema, ischemia, and infarctions in whole body (29). Similarly, final Hb F levels in hydroxyurea users did not differ from their pretreatment levels (30). The Multicenter Study of Hydroxyurea (MSH) studied 299 severely affected adults with the SCA, and compared the results of patients treated with hydroxyurea or placebo (31). The study particularly researched effects of hydroxyurea on painful crises, ACS, and requirement of blood transfusion. The outcomes were so overwhelming in the favour of hydroxyurea that the study was terminated after 22 months, and hydroxyurea was initiated for all patients. The MSH also demonstrated that patients treated with hydroxyurea had a 44% decrease in hospitalizations (31). In multivariable analyses, there was a strong and independent association of lower neutrophil counts with the lower crisis rates (31). But this study was performed just in severe SCA cases alone, and the rate of painful crises was decreased from 4.5 to 2.5 per year (31). Whereas we used all subtypes of the SCD with all clinical severity, and the rate of painful crises was decreased from 10.3 to 1.7 per year ($p < 0.000$) with an additional decreased severity of them (7.8/10 vs 2.2/10, $p < 0.000$) in the previous study (20). Parallel to our results, adult patients using hydroxyurea for frequent painful crises appear to have reduced mortality rate after a 9-year follow-up period (32). Although the underlying disease severity remains critical to determine prognosis, hydroxyurea may also decrease severity of disease and prolong survival (32). The complications start to be seen even in infancy in the SCD. For example, infants with lower hemoglobin values were more likely to have a higher incidence of clinical events such as ACS, painful crises, and lower neuropsychological scores, and hydroxyurea reduced the incidences of them (33). Hydroxyurea therapy in early years of life may protect splenic function, improve growth, and prevent end-organ insufficiencies. Transfusion programmes can also reduce all of the complications, but transfusions carry many risks including infections, iron overload, and development of allo-antibodies causing subsequent transfusions difficult.

Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) used to reduce pain, fever, inflammation, and acute thromboembolic events. Although aspirin has similar anti-inflammatory effects with the other NSAIDs, it also suppresses the normal functions of PLTs, irreversibly. This property causes aspirin being different from other NSAIDs, which are reversible inhibitors. Aspirin acts as an acetylating agent where an acetyl group is covalently attached to

a serine residue in the active site of the cyclooxygenase (COX) enzyme. Aspirin's ability to suppress the production of prostaglandins (PGs) and thromboxanes (TXs) is due to its irreversible inactivation of the COX enzyme required for PG and TX synthesis. PGs are the locally produced hormones with some diverse effects, including the transmission of pain into the brain and modulation of the hypothalamic thermostat and inflammation in the body. TXs are responsible for the aggregation of PLTs to form blood clots. In another definition, low-dose aspirin use irreversibly blocks the formation of TXA₂ in the PLTs, producing an inhibitory effect on the PLT aggregation during whole lifespan of the affected PLTs (8-9 days). Since PLTs do not have nucleus and DNA, they are unable to synthesize new COX enzyme once aspirin has inhibited the enzyme. The antithrombotic property of aspirin is useful to reduce the incidences of myocardial infarction, transient ischemic attack, and stroke (34). Heart attacks are caused primarily by blood clots, and low dose of aspirin is seen as an effective medical intervention to prevent a second myocardial infarction (35). According to the literature, aspirin may also be effective in prevention of colorectal cancers (36). On the other hand, aspirin has some side effects including gastric ulcers, gastric bleeding, worsening of asthma, and Reye syndrome in childhood and adolescence. Due to the risk of Reye syndrome, the US Food and Drug Administration recommends that aspirin or aspirin-containing products should not be prescribed for febrile patients under the age of 12 years (37). Eventually, the general recommendation to use aspirin in children has been withdrawn, and it was only recommended for Kawasaki disease (38). Reye syndrome is a rapidly worsening brain disease (38). The first detailed description of Reye syndrome was in 1963 by an Australian pathologist, Douglas Reye (39). The syndrome mostly affects children, but it can only affect fewer than one in a million children a year (39). Symptoms of Reye syndrome may include personality changes, confusion, seizures, and loss of consciousness (38). Although the liver toxicity typically occurs in the syndrome, jaundice is usually not seen with it, but the liver is enlarged in most cases (38). Although the death occurs in 20-40% of affected cases, about one third of survivors get a significant degree of brain damage (38). The cause of Reye syndrome is unknown (39). It usually starts just after recovery from a viral infection, such as influenza or chicken pox. About 90% of cases in children are associated with an aspirin use (39, 40). Inborn errors of metabolism are also the other risk factors, and the genetic testing for inborn errors of metabolism became available in developed countries in the 1980s (38). When aspirin use was withdrawn for children in the US and UK in the 1980s, a decrease of more than 90% in rates of Reye syndrome was seen (39). Early diagnosis improves outcomes, and treatment is supportive. Mannitol may be used in cases with the brain swelling (39). Due to the very low risk of Reye syndrome but much higher risk of death due to the SCD in children, aspirin should be added both into the acute and chronic phase treatments

with an anti-inflammatory dose even in childhood in the SCD (41). Warfarin is an anticoagulant, and first came into large-scale commercial use in 1948 as a rat poison. It was formally approved as a medication to treat blood clots in human being by the U.S. Food and Drug Administration in 1954. In 1955, warfarin's reputation as a safe and acceptable treatment was bolstered when President Dwight David Eisenhower was treated with warfarin following a massive and highly publicized heart attack. Eisenhower's treatment kickstarted a transformation in medicine whereby CHD, arterial plaques, and ischemic strokes were treated and protected against by using anticoagulants such as warfarin. Warfarin is found in the List of Essential Medicines of WHO. In 2020, it was the 58th most commonly prescribed medication in the United States. It does not reduce blood viscosity but inhibits blood coagulation. Warfarin is used to decrease the tendency for thrombosis, and it can prevent formation of future blood clots and reduce the risk of embolism. Warfarin is the best suited for anticoagulation in areas of slowly running blood such as in veins and the pooled blood behind artificial and natural valves, and in blood pooled in dysfunctional cardiac atria. It is commonly used to prevent blood clots in the circulatory system such as DVT and pulmonary embolism, and to protect against stroke in people who have atrial fibrillation (AF), valvular heart disease, or artificial heart valves. Less commonly, it is used following ST-segment elevation myocardial infarction and orthopedic surgery. The warfarin initiation regimens are simple, safe, and suitable to be used in ambulatory and in patient settings (42). Warfarin should be initiated with a 5 mg dose, or 2 to 4 mg in the very elderly. In the protocol of low-dose warfarin, the target international normalised ratio (INR) value is between 2.0 and 2.5, whereas in the protocol of standard-dose warfarin, the target INR value is between 2.5 and 3.5 (43). When warfarin is used and INR is in therapeutic range, simple discontinuation of the drug for five days is usually enough to reverse the effect, and causes INR to drop below 1.5 (44). Its effects can be reversed with phytomenadione (vitamin K1), fresh frozen plasma, or prothrombin complex concentrate, rapidly. Blood products should not be routinely used to reverse warfarin overdose, when vitamin K1 could work alone. Warfarin decreases blood clotting by blocking vitamin K epoxide reductase, an enzyme that reactivates vitamin K1. Without sufficient active vitamin K1, clotting factors II, VII, IX, and X have decreased clotting ability. The anticlotting protein C and protein S are also inhibited, but to a lesser degree. A few days are required for full effect to occur, and these effects can last for up to five days. The consensus agrees that patient self-testing and patient self-management are effective methods of monitoring oral anticoagulation therapy, providing outcomes at least as good as, and possibly better than, those achieved with an anticoagulation clinic. Currently available self-testing/self-management devices give INR results that are comparable with those obtained in laboratory testing. The only common side effect of warfarin is hemor-

rhage. The risk of severe bleeding is low with a yearly rate of 1-3% (45). All types of bleeding may occur, but the most severe ones are those involving the brain and spinal cord (45). The risk is particularly increased once the INR exceeds 4.5 (45). The risk of bleeding is increased further when warfarin is combined with antiplatelet drugs such as clopidogrel or aspirin (46). But thirteen publications from 11 cohorts including more than 48,500 total patients with more than 11,600 warfarin users were included in the meta-analysis (47). In patients with AF and non-end-stage CRD, warfarin resulted in a lower risk of ischemic stroke ($p=0.004$) and mortality ($p<0.00001$), but had no effect on major bleeding ($p>0.05$) (47). Similarly, warfarin resumption is associated with significant reductions in ischemic stroke even in patients with warfarin-associated intracranial hemorrhage (ICH) (48). Death occurred in 18.7% of patients who resumed warfarin and 32.3% who did not resume warfarin ($p=0.009$) (48). Ischemic stroke occurred in 3.5% of patients who resumed warfarin and 7.0% of patients who did not resume warfarin ($p=0.002$) (48). Whereas recurrent ICH occurred in 6.7% of patients who resumed warfarin and 7.7% of patients who did not resume warfarin without any significant difference in between ($p>0.05$) (48). On the other hand, patients with cerebral venous thrombosis (CVT) those were anticoagulated either with warfarin or dabigatran had low risk of recurrent venous thrombotic events (VTE), and the risk of bleeding was similar in both regimens, suggesting that both warfarin and dabigatran are safe and effective for preventing recurrent VTE in patients with CVT (49). Additionally, an INR value of about 1.5 achieved with an average daily dose of 4.6 mg warfarin, has resulted in no increase in the number of men ever reporting minor bleeding episodes, although rectal bleeding occurs more frequently in those men who report this symptom (50). Non-rheumatic AF increases the risk of stroke, presumably from atrial thromboemboli, and long-term low-dose warfarin therapy is highly effective and safe in preventing stroke in such patients (51). There were just two strokes in the warfarin group (0.41% per year) as compared with 13 strokes in the control group (2.98% per year) with a reduction of 86% in the risk of stroke ($p=0.0022$) (51). The mortality was markedly lower in the warfarin group, too ($p=0.005$) (51). The warfarin group had a higher rate of minor hemorrhage (38 vs 21 patients) but the frequency of bleedings that required hospitalization or transfusion was the same in both group ($p>0.05$) (51). Additionally, very-low-dose warfarin was a safe and effective method for prevention of thromboembolism in patients with metastatic breast cancer (52). The warfarin dose was 1 mg daily for 6 weeks, and was adjusted to maintain the INR value of 1.3 to 1.9 (52). The average daily dose was 2.6 mg, and the mean INR was 1.5 (52). On the other hand, new oral anticoagulants had a favourable risk-benefit profile with significant reductions in stroke, ICH, and mortality, and with similar major bleeding as for warfarin, but increased gastrointestinal bleeding (53). Interestingly, rivaroxaban and low-dose apixaban

were associated with increased risks of all cause mortality compared with warfarin (54). The mortality rate was 4.1% per year in the warfarin group, as compared with 3.7% per year with 110 mg of dabigatran and 3.6% per year with 150 mg of dabigatran ($p>0.05$ for both) in patients with AF in another study (55). On the other hand, infections, medical or surgical emergencies, or emotional stress-induced increased basal metabolic rate accelerates sickling, and an exaggerated capillary endothelial edema-induced myocardial infarction or stroke may cause sudden deaths in the SCD. So lifelong aspirin with an anti-inflammatory dose plus low-dose warfarin may be a life-saving treatment regimen even at childhood both to decrease severity of capillary endothelial inflammation and to prevent thromboembolic complications in the SCD (56).

COPD is the third leading cause of death with various underlying etiologies in whole world (57, 58). Aging, physical inactivity, sedentary lifestyle, animal-rich diet, smoking, alcohol, male gender, excess weight, chronic inflammations, prolonged infections, and cancers may be the major underlying causes. Beside smoking, regular alcohol consumption is also important for the pulmonary and systemic inflammatory process of the COPD, since COPD was one of the most common diagnoses in alcohol dependence (59). Furthermore, 30-day readmission rates were higher in the COPD patients with alcoholism (60). Probably an accelerated atherosclerotic process is the main structural background of functional changes that are characteristics of the COPD. The inflammatory process of vascular endothelium is enhanced by release of various chemicals by inflammatory cells, and it terminates with an advanced fibrosis, atherosclerosis, and pulmonary losses. COPD may actually be the pulmonary consequence of the systemic atherosclerotic process. Since beside the accelerated atherosclerotic process of the pulmonary vasculature, there are several reports about coexistence of associated endothelial inflammation all over the body in COPD (61, 62). For example, there may be close relationships between COPD, CHD, PAD, and stroke (63). Furthermore, two-third of mortality cases were caused by cardiovascular diseases and lung cancers in the COPD, and the CHD was the most common cause in a multi-center study of 5.887 smokers (64). When the hospitalizations were researched, the most common causes were the cardiovascular diseases, again (64). In another study, 27% of mortality cases were due to the cardiovascular diseases in the moderate and severe COPD (65). On the other hand, COPD may be the pulmonary consequence of the systemic atherosclerotic process caused by the hardened RBC in the SCD (57).

Digital clubbing is characterized by the increased normal angle of 165° between nailbed and fold, increased convexity of the nail fold, and thickening of the whole distal finger (66). Although the exact cause and significance is unknown, the chronic tissue hypoxia is highly suspected (67). In the previous study, only 40% of clubbing cases turned out to have significant underlying dis-

eases while 60% remained well over the subsequent years (18). But according to our experiences, digital clubbing is frequently associated with the pulmonary, cardiac, renal, and hepatic diseases and smoking which are characterized with chronic tissue hypoxia (5). As an explanation for that hypothesis, lungs, heart, kidneys, and liver are closely related organs which affect their functions in a short period of time. On the other hand, digital clubbing is also common in the SCD, and its prevalence was 10.8% in the present study. It probably shows chronic tissue hypoxia caused by disseminated endothelial damage, inflammation, edema, and fibrosis at the capillary level in the SCD. Beside the effects of SCD, smoking, alcohol, cirrhosis, CRD, CHD, and COPD, the higher prevalence of digital clubbing in males (14.8% vs 6.6%, $p<0.001$) may also show some additional role of male gender in the systemic atherosclerotic process.

Leg ulcers are seen in 10% to 20% of the SCD, and the ratio was 13.5% in the present study (68). Its prevalence increases with aging, male gender, and SCA (69). Similarly, its ratio was higher in males (19.8% vs 7.0%, $p<0.001$), and mean age of the leg ulcer cases was higher than the remaining patients (35.3 vs 29.8 years, $p<0.000$) in the present study. The leg ulcers have an intractable nature, and around 97% of them relapse in a period of one year (68). As an evidence of their atherosclerotic nature, the leg ulcers occur in the distal segments of the body with a lesser collateral blood flow (68). The hardened RBC induced chronic endothelial damage, inflammation, edema, and fibrosis at the capillary level may be the major causes, again (69). Prolonged exposure to the hardened bodies due to the pooling of blood in the lower extremities may also explain the leg but not arm ulcers in the SCD. The hardened RBC induced venous insufficiencies may also accelerate the process by pooling of causative bodies in the legs, and vice versa. Pooling of blood may also have some effects on development of venous ulcers, diabetic ulcers, Buerger's disease, digital clubbing, and onychomycosis in the lower extremities. Furthermore, probably pooling of blood is the cause of delayed wound and fracture healings in the lower extremities. Smoking and alcohol may also have some additional atherosclerotic effects on the ulcers in males. Hydroxyurea is the first drug that was approved by Food and Drug Administration in the SCD (70). It is an orally-administered, cheap, safe, and effective drug that blocks cell division by suppressing formation of deoxyribonucleotides which are the building blocks of DNA (11). Its main action may be the suppression of hyperproliferative WBCs and PLTs in the SCD (71). Although presence of a continuous damage of hardened RBC on vascular endothelium, severity of the destructive process is probably exaggerated by the patients' own immune systems. Similarly, lower WBCs counts were associated with lower crises rates, and if a tissue infarct occurs, lower WBCs counts may decrease severity of pain and tissue damage (30). According to our experiences, prolonged resolution of leg ulcers with hydroxyurea may also suggest

that the ulcers may be secondary to increased WBCs and PLTs counts induced exaggerated capillary endothelial inflammation and edema instead of the fibrosis, yet.

Cirrhosis was the 10th leading cause of death for men and the 12th for women in the United States in 2001 (6). Although the improvements of health services worldwide, the increased morbidity and mortality of cirrhosis may be explained by prolonged survival of the human being, and increased prevalence of excess weight all over the world. For example, nonalcoholic fatty liver disease (NAFLD) affects up to one third of the world population, and it became the most common cause of chronic liver disease even at childhood, nowadays (72). NAFLD is a marker of pathological fat deposition combined with a low-grade inflammation which results with hypercoagulability, endothelial dysfunction, and an accelerated atherosclerosis (72). Beside terminating with cirrhosis, NAFLD is associated with higher overall mortality rates as well as increased prevalences of cardiovascular diseases (73). Authors reported independent associations between NAFLD and impaired flow-mediated vasodilation and increased mean carotid artery intima-media thickness (CIMT) (74). NAFLD may be considered as one of the hepatic consequences of the metabolic syndrome and SCD (75). Probably smoking also takes role in the inflammatory process of the capillary endothelium in liver, since the systemic inflammatory effects of smoking on endothelial cells is well-known with Buerger's disease and COPD (76). Increased oxidative stress, inactivation of antiproteases, and release of proinflammatory mediators may terminate with the systemic atherosclerosis in smokers. The atherosclerotic effects of alcohol is much more prominent in hepatic endothelium probably due to the highest concentrations of its metabolites there. Chronic infectious or inflammatory processes and cancers may also terminate with an accelerated atherosclerosis in whole body (77). For example, chronic hepatitis C virus (HCV) infection raised CIMT, and normalization of hepatic function with HCV clearance may be secondary to reversal of favourable lipids observed with the chronic infection (77, 78). As a result, cirrhosis may also be another atherosclerotic consequence of the SCD.

CRD is also increasing all over the world that can also be explained by aging of the human being, and increased prevalence of excess weight all over the world (79, 80). Aging, physical inactivity, sedentary lifestyle, animal-rich diet, excess weight, smoking, alcohol, inflammatory or infectious processes, and cancers may be the major causes of the renal endothelial inflammation. The inflammatory process is enhanced by release of various chemicals by lymphocytes to repair the damaged endothelial cells of the renal arteriols. Due to the continuous irritation of the vascular endothelial cells, prominent changes develop in the architecture of the renal tissues with advanced atherosclerosis, tissue hypoxia, and infarcts (81). Excess weight induced hyperglycemia, dyslipidemia, elevated BPs, and insulin resistance may cause tissue inflamma-

tion and immune cell activation (82). For example, age ($p=0.04$), high-sensitivity C-reactive protein ($p=0.01$), mean arterial BPs ($p=0.003$), and DM ($p=0.02$) had significant correlations with the CIMT (80). Increased renal tubular sodium reabsorption, impaired pressure natriuresis, volume expansion due to the activations of sympathetic nervous system and renin-angiotensin system, and physical compression of kidneys by visceral fat tissue may be some mechanisms of the increased BPs with excess weight (83). Excess weight also causes renal vasodilation and glomerular hyperfiltration which initially serve as compensatory mechanisms to maintain sodium balance due to the increased tubular reabsorption (83). However, along with the increased BPs, these changes cause a hemodynamic burden on the kidneys in long term that causes chronic endothelial damage (84). With prolonged weight excess, there are increased urinary protein excretion, loss of nephron function, and exacerbated HT. With the development of dyslipidemia and DM in cases with excess weight, CRD progresses much more easily (83). On the other hand, the systemic inflammatory effects of smoking on endothelial cells may also be important in the CRD (85). Although some authors reported that alcohol was not related with the CRD (85), various metabolites of alcohol circulate even in the blood vessels of the kidneys and give harm to the renal vascular endothelium. Chronic inflammatory or infectious processes may also terminate with the accelerated atherosclerosis in the renal vasculature (77). Although CRD is due to the atherosclerotic process of the renal vasculature, there are close relationships between CRD and other atherosclerotic consequences of the metabolic syndrome including CHD, COPD, PAD, cirrhosis, and stroke (86, 87). For example, the most common cause of death was the cardiovascular diseases in the CRD again (88). The hardened RBC-induced capillary endothelial damage in the renal vasculature may be the main cause of CRD in the SCD. In another definition, CRD may just be one of the several atherosclerotic consequences of the metabolic syndrome and SCD, again (89).

Stroke is an important cause of death, and develops as an acute thromboembolic event on the chronic atherosclerotic background in most of the cases. Aging, male gender, smoking, alcohol, and excess weight may be the major underlying causes. Stroke is also a common complication of the SCD (90, 91). Similar to the leg ulcers, stroke is particularly higher in the SCA and cases with higher WBCs counts (92). Sickling induced capillary endothelial damage, activations of WBCs, PLTs, and coagulation system, and hemolysis may terminate with chronic capillary endothelial inflammation, edema, and fibrosis (93). Probably, stroke may not have a macrovascular origin in the SCD, and diffuse capillary endothelial inflammation, edema, and fibrosis may be much more important. Infections, inflammations, medical or surgical emergencies, and emotional stress may precipitate stroke by increasing basal metabolic rate and sickling. A significant reduction of stroke with hydroxyurea may also suggest that a significant proportion of cases

is developed due to the increased WBCs and PLTs counts-induced exaggerated capillary inflammation, edema, and fibrosis (94).

We know very well that several malignant cells are produced and cleaned by the immune system in human body everyday, and chronic and systemic inflammatory processes including SCD, rheumatoid arthritis, and systemic lupus erythematosus may increase the clearance of malignant cells from the circulation. First of all, the chronic and systemic inflammatory processes may alert the immune system, and provide a resistance against malignant cells in whole body. Secondly, they increase heart rate and cause fever, and induce an increased blood circulation all over the body. By this way, the natural killer cells can fight with the malignant cells much more effectively since they are the lymphocytes like B-cells and T-cells, and destroy infected and diseased cells, like cancer cells. Thirdly, the relatively increased basal metabolic rate during such chronic inflammatory processes also prevents excess weight and its consequences including DM, HT, immunosuppression, and malignancies (10). Fourthly, chronic and systemic inflammatory processes cause frequent hospitalizations which may cause early detection of some systemic problems in human body.

As a conclusion, infections, medical or surgical emergencies, or emotional stress-induced increased basal metabolic rate aggravates the sickling and capillary endothelial inflammation and edema, and terminates with disseminated tissue hypoxia, accelerated atherosclerosis, multiorgan failures, and sudden deaths even at relatively younger mean ages but not malignancies in the SCD. In another definition, chronic and systemic inflammatory processes may increase the clearance of malignant cells from the circulation.

References

- Widlansky ME, Gokce N, Keaney JF Jr, Vita JA. The clinical implications of endothelial dysfunction. *J Am Coll Cardiol.* 2003; 42(7): 1149-60.
- Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. *Lancet* 2005; 365(9468): 1415-28.
- Franklin SS, Barboza MG, Pio JR, Wong ND. Blood pressure categories, hypertensive subtypes, and the metabolic syndrome. *J Hypertens* 2006; 24(10): 2009-16.
- Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation.* 2002; 106(25): 3143-421.
- Helvacı MR, Aydın LY, Aydın Y. Digital clubbing may be an indicator of systemic atherosclerosis even at microvascular level. *HealthMED.* 2012; 6(12): 3977-81.
- Anderson RN, Smith BL. Deaths: leading causes for 2001. *Natl Vital Stat Rep* 2003; 52(9): 1-85.
- Helvacı MR, Gokce C, Davran R, Akkucuk S, Ugur M, Oruc C. Mortal quintet of sickle cell diseases. *Int J Clin Exp Med* 2015; 8(7): 11442-8.
- Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. *N Engl J Med* 1994; 330(23): 1639-44.
- Helvacı MR, Yaprak M, Abyad A, Pocock L. Atherosclerotic background of hepatosteatosis in sickle cell diseases. *World Family Med* 2018; 16(3): 12-8.
- Helvacı MR, Kaya H. Effect of sickle cell diseases on height and weight. *Pak J Med Sci* 2011; 27(2): 361-4.
- Helvacı MR, Aydın Y, Ayyıldız O. Hydroxyurea may prolong survival of sickle cell patients by decreasing frequency of painful crises. *HealthMED* 2013; 7(8): 2327-32.
- Mankad VN, Williams JP, Harpen MD, Mancı E, Longenecker G, Moore RB, et al. Magnetic resonance imaging of bone marrow in sickle cell disease: clinical, hematologic, and pathologic correlations. *Blood* 1990; 75(1): 274-83.
- Helvacı MR, Aydın Y, Ayyıldız O. Clinical severity of sickle cell anemia alone and sickle cell diseases with thalassemias. *HealthMED* 2013; 7(7): 2028-33.
- Fisher MR, Forfia PR, Chamera E, Houston-Harris T, Champion HC, Girgis RE, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. *Am J Respir Crit Care Med* 2009; 179(7): 615-21.
- Vestbo J, Hurd SS, Agustı AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med* 2013; 187(4): 347-65.
- Davies SC, Luce PJ, Win AA, Riordan JF, Brozovic M. Acute chest syndrome in sickle-cell disease. *Lancet* 1984; 1(8367): 36-8.
- Vandemergel X, Renneboog B. Prevalence, aetiologies and significance of clubbing in a department of general internal medicine. *Eur J Intern Med* 2008; 19(5): 325-9.
- Schamroth L. Personal experience. *S Afr Med J* 1976; 50(9): 297-300.
- Parfrey NA, Moore W, Hutchins GM. Is pain crisis a cause of death in sickle cell disease? *Am J Clin Pathol* 1985; 84: 209-12.
- Helvacı MR, Ayyıldız O, Gundogdu M. Hydroxyurea therapy and parameters of health in sickle cell patients. *HealthMED* 2014; 8(4): 451-6.
- Helvacı MR, Tonyalı O, Yaprak M, Abyad A, Pocock L. Increased sexual performance of sickle cell patients with hydroxyurea. *World Family Med* 2019; 17(4): 28-33.
- Helvacı MR, Atci N, Ayyıldız O, Muftuoğlu OE, Pocock L. Red blood cell supports in severe clinical conditions in sickle cell diseases. *World Family Med* 2016; 14(5): 11-8.
- Helvacı MR, Ayyıldız O, Gundogdu M. Red blood cell transfusions and survival of sickle cell patients. *HealthMED* 2013; 7(11): 2907-12.
- Miller ST, Sleeper LA, Pegelow CH, Enos LE, Wang WC, Weiner SJ, et al. Prediction of adverse outcomes in children with sickle cell disease. *N Engl J Med* 2000; 342: 83-9.

25. Balkaran B, Char G, Morris JS, Thomas PW, Serjeant BE, Serjeant GR. Stroke in a cohort of patients with homozygous sickle cell disease. *J Pediatr* 1992; 120: 360-6.
26. Cole TB, Sprinkle RH, Smith SJ, Buchanan GR. Intravenous narcotic therapy for children with severe sickle cell pain crisis. *Am J Dis Child* 1986; 140: 1255-9.
27. Miller BA, Platt O, Hope S, Dover G, Nathan DG. Influence of hydroxyurea on fetal hemoglobin production in vitro. *Blood* 1987; 70(6): 1824-9.
28. Platt OS. Is there treatment for sickle cell anemia? *N Engl J Med* 1988; 319(22): 1479-80.
29. Helvacı MR, Aydoğan F, Sevinc A, Camcı C, Dilek I. Platelet and white blood cell counts in severity of sickle cell diseases. *Pren Med Argent* 2014; 100(1): 49-56.
30. Charache S. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. *Semin Hematol* 1997; 34(3): 15-21.
31. Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. *Medicine (Baltimore)* 1996; 75(6): 300-26.
32. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. *JAMA* 2003; 289(13): 1645-51.
33. Lebensburger JD, Miller ST, Howard TH, Casella JF, Brown RC, Lu M, et al. BABY HUG Investigators. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. *Pediatr Blood Cancer* 2012; 59(4): 675-8.
34. Toghi H, Konno S, Tamura K, Kimura B, Kawano K. Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. *Stroke* 1992; 23(10): 1400-3.
35. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. *Lancet* 2009; 373(9678): 1849-60.
36. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. *Lancet Oncol* 2012; 13(5): 518-27.
37. Macdonald S. Aspirin use to be banned in under 16 year olds. *BMJ* 2002; 325(7371): 988.
38. Schrör K. Aspirin and Reye syndrome: a review of the evidence. *Paediatr Drugs* 2007; 9(3): 195-204.
39. Pugliese A, Beltramo T, Torre D. Reye's and Reye's-like syndromes. *Cell Biochem Funct* 2008; 26(7): 741-6.
40. Hurwitz ES. Reye's syndrome. *Epidemiol Rev* 1989; 11: 249-53.
41. Meremikwu MM, Okomo U. Sickle cell disease. *BMJ Clin Evid* 2011; 2011: 2402.
42. Mohamed S, Fong CM, Ming YJ, Kori AN, Wahab SA, Ali ZM. Evaluation of an initiation regimen of warfarin for international normalized ratio target 2.0 to 3.0. *J Pharm Technol* 2021; 37(6): 286-92.
43. Chu MWA, Ruel M, Graeve A, Gerdisch MW, Ralph J, Damiano Jr RJ, Smith RL. Low-dose vs standard warfarin after mechanical mitral valve replacement: A randomized trial. *Ann Thorac Surg* 2023; 115(4): 929-38.
44. Crowther MA, Douketis JD, Schnurr T, Steidl L, Mera V, Ultori C, et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneously vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. *Ann Intern Med* 2002; 137(4): 251-4.
45. Brown DG, Wilkerson EC, Love WE. A review of traditional and novel oral anticoagulant and antiplatelet therapy for dermatologists and dermatologic surgeons. *J Am Acad Dermatol* 2015; 72(3): 524-34.
46. Delaney JA, Opatrny L, Brophy JM, Suissa S. Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. *CMAJ*. 2007; 177(4): 347-51.
47. Dahal K, Kunwar S, Rijal J, Schulman P, Lee J. Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies. *Chest*. 2016; 149(4): 951-9.
48. Chai-Adisaksopha C, Lorio A, Hillis C, Siegal D, Witt DM, Schulman S, et al. Warfarin resumption following anticoagulant-associated intracranial hemorrhage: A systematic review and meta-analysis. *Thromb Res*. 2017; 160: 97-104.
49. Ferro JM, Coutinho JM, Dentali F, Kobayashi A, Alasheev A, Canhao P, et al. Safety and efficacy of dabigatran etexilate vs dose-adjusted warfarin in patients with cerebral venous thrombosis: A randomized clinical trial. *JAMA Neurol*. 2019; 76(12): 1457-65.
50. Meade TW. Low-dose warfarin and low-dose aspirin in the primary prevention of ischemic heart disease. *Am J Cardiol*. 1990; 65(6): 7C-11C.
51. Singer DE, Hughes RA, Gress DR, Sheehan MA, Oertel LB, Maraventano SW, et al. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. *N Engl J Med*. 1990; 323(22): 1505-11.
52. Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanya A, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. *Lancet*. 1994; 343(8902): 886-9.
53. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet*. 2014; 383(9921): 955-62.
54. Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. *BMJ*. 2018; 362: k2505.

55. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2009; 361(12): 1139-51.
56. Helvacı MR, Vural A, Onay K, Abyad A, Pocock L. Low-dose warfarin may be a life-saving treatment regimen in sickle cell diseases. *World Family Med*. 2023; 21(7): 21-35.
57. Helvacı MR, Erden ES, Aydin LY. Atherosclerotic background of chronic obstructive pulmonary disease in sickle cell patients. *HealthMED*. 2013; 7(2): 484-8.
58. Rennard SI, Drummond MB. Early chronic obstructive pulmonary disease: definition, assessment, and prevention. *Lancet*. 2015; 385(9979): 1778-88.
59. Schoepf D, Heun R. Alcohol dependence and physical comorbidity: Increased prevalence but reduced relevance of individual comorbidities for hospital-based mortality during a 12.5-year observation period in general hospital admissions in urban North-West England. *Eur Psychiatry*. 2015; 30(4): 459-68.
60. Singh G, Zhang W, Kuo YF, Sharma G. Association of Psychological Disorders With 30-Day Readmission Rates in Patients With COPD. *Chest*. 2016; 149(4): 905-15.
61. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. *JAMA*. 1998; 279(18): 1477-82.
62. Mannino DM, Watt G, Hole D, Gillis C, Hart C, McConnachie A, et al. The natural history of chronic obstructive pulmonary disease. *Eur Respir J*. 2006; 27(3): 627-43.
63. Mapel DW, Hurley JS, Frost FJ, Petersen HV, Picchi MA, Coultas DB. Health care utilization in chronic obstructive pulmonary disease. A case-control study in a health maintenance organization. *Arch Intern Med*. 2000; 160(17): 2653-58.
64. Anthonisen NR, Connett JE, Enright PL, Manfreda J, Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. *Am J Respir Crit Care Med*. 2002; 166(3): 333-9.
65. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA; TORCH Clinical Endpoint Committee. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. *Thorax*. 2007; 62(5): 411-5.
66. Myers KA, Farquhar DR. The rational clinical examination. Does this patient have clubbing? *JAMA*. 2001; 286(3): 341-7.
67. Toovey OT, Eisenhauer HJ. A new hypothesis on the mechanism of digital clubbing secondary to pulmonary pathologies. *Med Hypotheses*. 2010; 75(6): 511-3.
68. Trent JT, Kirsner RS. Leg ulcers in sickle cell disease. *Adv Skin Wound Care*. 2004; 17(8): 410-6.
69. Minniti CP, Eckman J, Sebastiani P, Steinberg MH, Ballas SK. Leg ulcers in sickle cell disease. *Am J Hematol*. 2010; 85(10): 831-3.
70. Yawn BPs, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. *JAMA*. 2014; 312(10): 1033-48.
71. Helvacı MR, Aydoğan F, Sevinc A, Camcı C, Dilek I. Platelet and white blood cell counts in severity of sickle cell diseases. *HealthMED*. 2014; 8(4): 477-82.
72. Bhatia LS, Curzen NP, Calder PC, Byrne CD. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? *Eur Heart J*. 2012; 33(10): 1190-1200.
73. Pacifico L, Nobili V, Anania C, Verdecchia P, Chiesa C. Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. *World J Gastroenterol*. 2011; 17(26): 3082-91.
74. Mawatari S, Uto H, Tsubouchi H. Chronic liver disease and arteriosclerosis. *Nihon Rinsho*. 2011; 69(1): 153-7.
75. Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. *Curr Pharm Des*. 2010; 16(17): 1941-51.
76. Helvacı MR, Aydin LY, Aydin Y. Chronic obstructive pulmonary disease may be one of the terminal end points of metabolic syndrome. *Pak J Med Sci*. 2012; 28(3): 376-9.
77. Mostafa A, Mohamed MK, Saeed M, Hasan A, Fontanet A, Godsland I, et al. Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors. *Gut*. 2010; 59(8): 1135-40.
78. Helvacı MR, Ayyıldız O, Gundogdu M, Aydin Y, Abyad A, Pocock L. Hyperlipoproteinemias may actually be acute phase reactants in the plasma. *World Family Med*. 2018; 16(1): 7-10.
79. Levin A, Hemmelgarn B, Culleton B, Tobe S, McFarlane P, Ruzicka M, et al. Guidelines for the management of chronic kidney disease. *CMAJ*. 2008; 179(11): 1154-62.
80. Nassiri AA, Hakemi MS, Asadzadeh R, Faizei AM, Alatab S, Miri R, et al. Differences in cardiovascular disease risk factors associated with maximum and mean carotid intima-media thickness among hemodialysis patients. *Iran J Kidney Dis*. 2012; 6(3): 203-8.
81. Helvacı MR, Gokce C, Sahan M, Hakimoglu S, Coskun M, Gozukur KH. Venous involvement in sickle cell diseases. *Int J Clin Exp Med*. 2016; 9(6): 11950-7.
82. Xia M, Guerra N, Sukhova GK, Yang K, Miller CK, Shi GP, et al. Immune activation resulting from NKG2D/ligand interaction promotes atherosclerosis. *Circulation*. 2011; 124(25): 2933-43.
83. Hall JE, Henegar JR, Dwyer TM, Liu J, da Silva AA, Kuo JJ, et al. Is obesity a major cause of chronic kidney disease? *Adv Ren Replace Ther*. 2004; 11(1): 41-54.
84. Nerpin E, Ingelsson E, Risérus U, Helmersson-Karlqvist J, Sundström J, Jobs E, et al. Association between glomerular filtration rate and endothelial function in an elderly community cohort. *Atherosclerosis*. 2012; 224(1): 242-6.
85. Stengel B, Tarver-Carr ME, Powe NR, Eberhardt MS, Brancati FL. Lifestyle factors, obesity and the risk of chronic kidney disease. *Epidemiology*. 2003; 14(4): 479-87.
86. Bonora E, Targher G. Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. *Nat Rev Gastroenterol Hepatol*. 2012; 9(7): 372-81.

87. Helvacı MR, Cayir S, Halici H, Sevinc A, Camci C, Sencan H, et al. Acute chest syndrome and coronavirus disease may actually be genetically determined exaggerated immune response syndromes particularly in pulmonary capillaries. *World Family Med.* 2024; 22(3): 6-16.
88. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, et al. Chronic kidney disease and mortality risk: a systematic review. *J Am Soc Nephrol.* 2006; 17(7): 2034-47.
89. Helvacı MR, Aydin Y, Aydin LY. Atherosclerotic background of chronic kidney disease in sickle cell patients. *HealthMED.* 2013; 7(9): 2532-7.
90. DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White DA, Sarnaik SA, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. *N Engl J Med.* 2014; 371(8): 699-710.
91. Gueguen A, Mahevas M, Nzouakou R, Hosseini H, Habibi A, Bachir D, et al. Sickle-cell disease stroke throughout life: a retrospective study in an adult referral center. *Am J Hematol.* 2014; 89(3): 267-72.
92. Majumdar S, Miller M, Khan M, Gordon C, Forsythe A, Smith MG, et al. Outcome of overt stroke in sickle cell anaemia, a single institution's experience. *Br J Haematol.* 2014; 165(5): 707-13.
93. Kossorotoff M, Grevent D, de Montalembert M. Cerebral vasculopathy in pediatric sickle-cell anemia. *Arch Pediatr.* 2014; 21(4): 404-14.
94. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. *N Engl J Med.* 1995; 332(20): 1317-22.